Loading…
Dividends declared (per SOCE filings): FY2022 24,397 · FY2023 17,641 · FY2024 8,335 — 3-yr total 50,372
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company is a pharmaceutical company engaged in purchasing, processing, warehousing and wholesale distribution of pharmaceutical products across multiple countries.
| Ratio | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Margins | ||||||||
| Gross Margin | 67.0% | 52.9% | 65.1% | 57.8% | 55.4% | 49.9% | 33.1% | 39.9% |
| EBITDA Margin | 60.7% | 46.2% | 58.6% | 52.3% | 49.3% | 32.9% | 21.3% | 31.6% |
| EBITDAR | 24,358 | 18,410 | 24,195 | 30,053 | 32,609 | 15,165 | 6,337 | 12,737 |
| EBITDAR Margin | 60.7% | 46.2% | 58.6% | 52.3% | 49.3% | 32.9% | 21.3% | 31.6% |
| EBIT Margin | 60.7% | 46.2% | 58.6% | 52.3% | 49.3% | 32.9% | 21.3% | 31.6% |
| Net Profit Margin | 58.0% | 5.1% | 68.0% | 64.7% | 2.1% | 9.3% | 14.6% | 19.8% |
| Operating Expense % of Sales | 6.3% | 6.7% | 6.4% | 5.5% | 6.1% | 16.9% | 11.8% | 8.2% |
| Returns | ||||||||
| Return on Assets (ROA) | 33.9% | 3.2% | 37.2% | 36.8% | 2.0% | 13.6% | 18.8% | 32.3% |
| Return on Equity (ROE) | 37.6% | 3.8% | 43.4% | 43.2% | 2.4% | 19.0% | 46.7% | 89.6% |
| ROIC [EBIT / Invested Capital] | 39.6% | 33.7% | 36.5% | 34.2% | 55.2% | 69.0% | 68.4% | 143.2% |
| Leverage & debt balances | ||||||||
| Debt-to-Assets | 2.2% | 2.9% | 2.6% | 2.2% | 2.9% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.02x | 0.03x | 0.03x | 0.03x | 0.03x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.06x | 0.10x | 0.08x | 0.07x | 0.06x | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 90.1% | 85.1% | 85.7% | 85.1% | 83.5% | 71.3% | 40.2% | 36.0% |
| Net Debt | -392 | 992 | 1,546 | 1,849 | 805 | -606 | -5 | -5 |
| Cash & Equivalents | 1,896 | 812 | 384 | 334 | 1,228 | 606 | 5 | 5 |
| Total Debt | 1,504 | 1,804 | 1,930 | 2,184 | 2,033 | N/A | N/A | N/A |
| Liquidity & working capital | ||||||||
| Current Ratio | 13.76x | 8.23x | 8.46x | 7.84x | 7.33x | 5.19x | 3.05x | 1.56x |
| Quick Ratio | 12.88x | 7.70x | 7.26x | 6.90x | 6.55x | 4.83x | 2.54x | 1.40x |
| Cash Ratio | 0.38x | 0.11x | 0.04x | 0.03x | 0.13x | 0.07x | 0.00x | 0.00x |
| Total Current Assets | 68,584 | 62,972 | 75,406 | 101,032 | 69,787 | 47,254 | 41,874 | 24,687 |
| Total Current Liabilities | 4,984 | 7,655 | 8,914 | 12,895 | 9,519 | 9,096 | 13,748 | 15,803 |
| Inventory | 4,412 | 4,005 | 10,650 | 12,094 | 7,482 | 3,294 | 6,909 | 2,570 |
| Trade Receivables | 61,929 | 57,768 | 64,371 | 88,604 | 61,077 | 27,738 | 16,048 | 22,109 |
| Trade Payables | 4,343 | 6,540 | 8,194 | 11,904 | 8,408 | 6,567 | 11,097 | 12,932 |
| Net Working Capital | 63,600 | 55,317 | 66,491 | 88,137 | 60,268 | 38,158 | 28,126 | 8,884 |
| Net Working Capital % of Revenue | 158.6% | 138.8% | 161.1% | 153.4% | 91.1% | 82.9% | 94.7% | 22.1% |
| Trade Working Capital | 61,998 | 55,233 | 66,827 | 88,793 | 60,151 | 24,465 | 11,860 | 11,747 |
| Trade Working Capital % of Revenue | 154.6% | 138.6% | 161.9% | 154.5% | 90.9% | 53.1% | 39.9% | 29.2% |
| Change in Trade Working Capital | N/A | -6,765 | 11,594 | 21,966 | -28,643 | -35,686 | -12,605 | -113 |
| Turnover & efficiency | ||||||||
| Inventory Turnover | 3.00x | 4.69x | 1.35x | 2.00x | 3.95x | 7.01x | 2.87x | 9.41x |
| Days Inventory Outstanding (DIO) | 121.8 | 77.9 | 269.8 | 182.2 | 92.4 | 52.1 | 127.0 | 38.8 |
| Receivables Turnover | 0.65x | 0.69x | 0.64x | 0.65x | 1.08x | 1.66x | 1.85x | 1.82x |
| Days Sales Outstanding (DSO) | 563.7 | 529.2 | 569.4 | 562.8 | 336.9 | 219.9 | 197.3 | 200.5 |
| Payables Turnover | 3.05x | 2.87x | 1.76x | 2.04x | 3.51x | 3.51x | 1.79x | 1.87x |
| Days Payable Outstanding (DPO) | 119.8 | 127.2 | 207.6 | 179.3 | 103.9 | 103.9 | 204.0 | 195.1 |
| Cash Conversion Cycle | 565.6 days | 479.9 days | 631.6 days | 565.6 days | 325.5 days | 168.1 days | 120.3 days | 44.2 days |
| Asset Turnover | 0.58x | 0.63x | 0.55x | 0.57x | 0.95x | 1.45x | 1.29x | 1.63x |
| Cash flow & dividends | ||||||||
| Operating Cash Flow | 7,278 | 9,189 | 16,604 | 15,797 | 30,017 | 23,774 | 17,039 | 8,348 |
| Free Cash Flow (OCF − Capex proxy) | 7,278 | 9,189 | 16,604 | 15,797 | 30,017 | 23,774 | 17,039 | 8,416 |
| Cash Conversion (OCF / EBITDA) | 29.9% | 49.9% | 68.6% | 52.6% | 92.0% | 156.8% | 268.9% | 65.5% |
| Dividends Declared | 6,317 | 10,273 | 17,031 | 15,831 | 29,122 | 24,397 | 17,641 | 8,335 |
| Dividend Payout Ratio | 27.1% | 509.7% | 60.7% | 42.6% | 2084.9% | 568.2% | 408.3% | 104.6% |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →